Suppression of NASH-Related HCC by Farnesyltransferase Inhibitor through Inhibition of Inflammation and Hypoxia-Inducible Factor-1α Expression
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms241411546 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Kohei Yamada und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Saga University Faculty of Medicine, Saga 849-8501, Japan. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Non-alcoholic Fatty Liver Disease, Liver Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science KAKENHI Grant-in-Aid for Scientific Research.
Abstract (Originalsprache)
Inflammatory processes play major roles in carcinogenesis and the progression of hepatocellular carcinoma (HCC) derived from non-alcoholic steatohepatitis (NASH). But, there are no therapies for NASH-related HCC, especially focusing on these critical steps. Previous studies have reported that farnesyltransferase inhibitors (FTIs) have anti-inflammatory and anti-tumor effects. However, the influence of FTIs on NASH-related HCC has not been elucidated. In hepatoblastoma and HCC cell lines, HepG2, Hep3B, and Huh-7, we confirmed the expression of hypoxia-inducible factor (HIF)-1α, an accelerator of tumor aggressiveness and the inflammatory response. We established NASH-related HCC models under inflammation and free fatty acid burden and confirmed that HIF-1α expression was increased under both conditions. Tipifarnib, which is an FTI, strongly suppressed increased HIF-1α, inhibited cell proliferation, and induced apoptosis. Simultaneously, intracellular interleukin-6 as an inflammation marker was increased under both conditions and significantly suppressed by tipifarnib. Additionally, tipifarnib suppressed the expression of phosphorylated nuclear factor-κB and transforming growth factor-β. Finally, in a NASH-related HCC mouse model burdened with diethylnitrosamine and a high-fat diet, tipifarnib significantly reduced tumor nodule formation in association with decreased serum interleukin-6. In conclusion, tipifarnib has anti-tumor and anti-inflammatory effects in a NASH-related HCC model and may be a promising new agent to treat this disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, Saga University Faculty of Medicine, Saga 849-8501, Japan.
- Department of Pathology, Saga University Faculty of Medicine, Saga 849-8501, Japan.
- Department of Surgery, National Hospital Organization Higashisaga Hospital, Saga 849-0101, Japan.
ORCID-Profile: Keita Kai
Förderung
- Japan Society for the Promotion of Science KAKENHI Grant-in-Aid for Scientific Research
Zitieren
APA
Yamada, K., Tanaka, T., Kai, K., Matsufuji, S., Ito, K., Kitajima, Y., Manabe, T., & Noshiro, H. (2023). Suppression of NASH-Related HCC by Farnesyltransferase Inhibitor through Inhibition of Inflammation and Hypoxia-Inducible Factor-1α Expression. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241411546
Vancouver
Yamada K, Tanaka T, Kai K, Matsufuji S, Ito K, Kitajima Y, et al. Suppression of NASH-Related HCC by Farnesyltransferase Inhibitor through Inhibition of Inflammation and Hypoxia-Inducible Factor-1α Expression. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms241411546
BibTeX
@article{Yamada2023,
author = {Yamada, Kohei and Tanaka, Tomokazu and Kai, Keita and Matsufuji, Shohei and Ito, Kotaro and Kitajima, Yoshihiko and Manabe, Tatsuya and Noshiro, Hirokazu},
title = {Suppression of NASH-Related HCC by Farnesyltransferase Inhibitor through Inhibition of Inflammation and Hypoxia-Inducible Factor-1α Expression},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms241411546}
}
EUVIMED